Beta Bionics, Inc. BBNX
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 119.01M | 110.24M | 100.25M | 88.57M | 78.02M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 119.01M | 110.24M | 100.25M | 88.57M | 78.02M |
| Cost of Revenue | 49.61M | 47.24M | 44.71M | 40.29M | 35.95M |
| Gross Profit | 69.40M | 63.00M | 55.54M | 48.28M | 42.08M |
| SG&A Expenses | 113.50M | 102.76M | 92.43M | 83.00M | 73.79M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 202.03M | 187.55M | 171.93M | 157.16M | 140.55M |
| Operating Income | -83.02M | -77.31M | -71.68M | -68.59M | -62.53M |
| Income Before Tax | -72.97M | -66.44M | -73.20M | -77.84M | -73.37M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -72.97 | -66.44 | -73.20 | -77.84 | -73.37 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -72.97M | -66.44M | -73.20M | -77.84M | -73.37M |
| EBIT | -83.02M | -77.31M | -71.68M | -68.59M | -62.53M |
| EBITDA | -80.80M | -75.46M | -70.11M | -67.33M | -61.31M |
| EPS Basic | -1.65 | -1.51 | -1.95 | -4.36 | -5.50 |
| Normalized Basic EPS | -1.03 | -0.94 | -1.22 | -2.73 | -3.44 |
| EPS Diluted | -1.65 | -1.51 | -1.95 | -4.36 | -5.50 |
| Normalized Diluted EPS | -1.03 | -0.94 | -1.22 | -2.73 | -3.44 |
| Average Basic Shares Outstanding | 176.81M | 175.66M | 161.93M | 124.41M | 87.43M |
| Average Diluted Shares Outstanding | 176.81M | 175.66M | 161.93M | 124.41M | 87.43M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |